Predictive value of plasma HIV RNA level on rate of CD4 T-cell decline in untreated HIV infection

被引:218
作者
Rodriguez, Benigno
Sethi, Ajay K.
Cheruvu, Vinay K.
Mackay, Wilma
Bosch, Ronald J.
Kitahata, Mari
Boswell, Stephen L.
Mathews, W. Christopher
Bangsberg, David R.
Martin, Jeffrey
Whalen, Christopher C.
Sieg, Scott
Yadavalli, Suhrida
Deeks, Steven G.
Lederman, Michael M.
机构
[1] Case Western Reserve Univ, Ctr AIDS Res, Cleveland, OH 44106 USA
[2] Case Western Reserve Univ, Ctr Modern Epidemiol Infect Dis, Cleveland, OH 44106 USA
[3] Harvard Univ, Sch Publ Hlth, Dept Biostat, Boston, MA 02115 USA
[4] Univ Washington, Dept Med, Seattle, WA USA
[5] Harvard Univ, Sch Med, Dept Med, Boston, MA USA
[6] Univ Calif San Diego, Dept Med, San Diego, CA 92103 USA
[7] Univ Calif San Francisco, Dept Med & Epidemiol, San Francisco, CA 94143 USA
[8] Univ Calif San Francisco, Dept Med, San Francisco, CA USA
来源
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION | 2006年 / 296卷 / 12期
关键词
D O I
10.1001/jama.296.12.1498
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Context Plasma human immunodeficiency virus (HIV) RNA level predicts HIV disease progression, but the extent to which it explains the variability in rate of CD4 cell depletion is poorly characterized. Objective To estimate the proportion of variability in rate of CD4 cell loss predicted by presenting plasma HIV RNA levels in untreated HIV-infected persons. Design Repeated-measures analyses of 2 multicenter cohorts, comprising observations beginning on May 12, 1984, and ending on August 26, 2004. Analyses were conducted between August 2004 and March 2006. Setting Two cohorts of HIV-infected persons: patients followed up at 4 US teaching medical institutions or participating in either the Research in Access to Care for the Homeless Cohort (REACH) or the San Francisco Men's Health Study (SFMHS) cohorts and participants in the Multicenter AIDS Cohort Study (MACS) cohort. Participants Antiretroviral treatment-naive, chronically HIV-infected persons (n = 1289 and n = 1512 for each of the 2 cohorts) untreated during the observation period (>= 6 months) and with at least 1 HIV RNA level and 2 CD4 cell counts available. Approximately 35% were nonwhite, and 35% had risk factors other than male-to-male sexual contact. Main Outcome Measures The extent to which presenting plasma HIV RNA level could explain the rate of model-derived yearly CD4 cell loss, as estimated by the coefficient of determination (R-2). Results In both cohorts, higher presenting HIV RNA levels were associated with greater subsequent CD4 cell decline. In the study cohort, median model-estimated CD4 cell decrease among participants with HIV RNA levels of 500 or less, 501 to 2000, 2001 to 10 000, 10 001 to 40 000, and more than 40 000 copies/mL were 20, 39, 48, 56, and 78 cells/mu L, respectively. Despite this trend across broad categories of HIV RNA levels, only a small proportion of CD4 cell loss variability (4%-6%) could be explained by presenting plasma HIV RNA level. Analyses using multiple HIV RNA measurements or restricting to participants with high HIV RNA levels improved this correlation minimally (R-2, 0.09), and measurement error was estimated to attenuate these associations only marginally (deattenuated R-2 in the 2 cohorts, 0.05 and 0.08, respectively). Conclusions Presenting HIV RNA level predicts the rate of CD4 cell decline only minimally in untreated persons. Other factors, as yet undefined, likely drive CD4 cell losses in HIV infection. These findings have implications for treatment decisions in HIV infection and for understanding the pathogenesis of progressive immune deficiency.
引用
收藏
页码:1498 / 1506
页数:9
相关论文
共 48 条
[1]  
Anastos K, 2000, J ACQ IMMUN DEF SYND, V24, P218
[2]   Do HIV type 1 RNA levels provide additional prognostic value to CD4+ T lymphocyte counts in patients with advanced HIV type 1 infection? [J].
Arduino, JM ;
Fischl, MA ;
Stanley, K ;
Collier, AC ;
Spiegelman, D .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 2001, 17 (12) :1099-1105
[3]  
*BHIVA EX COMM, 2005, BRIT HIV ASS BHIVA G, P28
[4]   Increased numbers of primed activated CD8+CD38+CD45RO+ T cells predict the decline of CD4+ T cells in HIV-1-infected patients [J].
Bofill, M ;
Mocroft, A ;
Lipman, M ;
Medina, E ;
Borthwick, NJ ;
Sabin, CA ;
Timms, A ;
Winter, M ;
Baptista, L ;
Johnson, MA ;
Lee, CA ;
Phillips, AN ;
Janossy, G .
AIDS, 1996, 10 (08) :827-834
[5]   The contribution of assay variation and biological variation to the total variability of plasma HIV-1 RNA measurements [J].
Brambilla, D ;
Reichelderfer, PS ;
Bremer, JW ;
Shapiro, DE ;
Hershow, RC ;
Katzenstein, DA ;
Hammer, SM ;
Jackson, B ;
Collier, AC ;
Sperling, RS ;
Fowler, MG ;
Coombs, RW .
AIDS, 1999, 13 (16) :2269-2279
[6]   Simian immunodeficiency virus replicates to high levels in naturally infected African green monkeys without inducing immunologic or neurologic disease [J].
Broussard, SR ;
Staprans, SI ;
White, R ;
Whitehead, EM ;
Feinberg, MB ;
Allan, JS .
JOURNAL OF VIROLOGY, 2001, 75 (05) :2262-2275
[7]   Randomised placebo-controlled trial of ritonavir in advanced HIV-1 disease [J].
Cameron, DW ;
Heath-Chiozzi, M ;
Danner, S ;
Cohen, C ;
Kravcik, S ;
Maurath, C ;
Sun, E ;
Henry, D ;
Rode, R ;
Potthoff, A ;
Leonard, J .
LANCET, 1998, 351 (9102) :543-549
[8]   Immune activation set point during early FHV infection predicts subsequent CD4+ T-cell changes independent of viral load [J].
Deeks, SG ;
Kitchen, CMR ;
Liu, L ;
Guo, H ;
Gascon, R ;
Narváez, AB ;
Hunt, P ;
Martin, JN ;
Kahn, JO ;
Levy, J ;
McGrath, MS ;
Hecht, FM .
BLOOD, 2004, 104 (04) :942-947
[9]  
*DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1, P4
[10]  
*DHHS PAN ANT GUID, 2006, GUID US ANT AG HIV 1